Trials / Recruiting
RecruitingNCT06816823
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
A Clinical Study of CAR-NK Cells (CL-NK-001) in Patients With Advanced Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.
Detailed description
A dose-escalation study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-001) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CL-NK-001 | Dose level 1 (5 × 10\^8 cells); dose level 2 (15 × 10\^8 cells); dose level 3 (30 × 10\^8 cells); additional dose levels (investigator's discretion). |
Timeline
- Start date
- 2025-04-07
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
- First posted
- 2025-02-10
- Last updated
- 2025-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06816823. Inclusion in this directory is not an endorsement.